Phase II open-label study evaluating hemostatic activity, pharmacokinetics and safety of recombinant porcine factor VIII (OBI-1) in hemophilia A patients with alloantibody inhibitors directed against human factor VIII - Mahlangu, J; Andreeva, TA; Macfarlane, D (Blood, 2007)
et al.